Pancreatic Cancer Research

ResearcherStony Brook UniversityActive in the last 2 years

Shixiang Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-3700-7767; OpenAlex author ID A5004837674. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: none · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 25

  1. A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer. Last author DOI 10.1016/j.bioactmat.2025.12.039↗
  2. SLC6A14-mediated carnitine transmembrane uptake from PPARγ+ cancer-associated fibroblasts promotes recurrence of pancreatic cancer. Last author DOI 10.1136/gutjnl-2025-336116↗
  3. Establishment of M2 macrophage-related prognostic signature in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12672-025-02838-z↗
  4. The role of the aging process and related factor EMP1 in promoting progression of resectable pancreatic cancer. Co-author DOI 10.1016/j.gendis.2024.101490↗
  5. Increased PRIM2 Expression Associated With Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000002387↗
  6. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance. Co-author DOI 10.1016/j.drup.2023.101027↗
  7. Identifying suitable candidates for pancreaticoduodenectomy with extended lymphadenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.07.405↗
  8. Strategic insights into the cultivation of pancreatic cancer organoids from endoscopic ultrasonography-guided biopsy tissue. Co-author DOI 10.3748/wjg.v30.i42.4532↗
  9. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Co-author DOI 10.3389/fonc.2023.1138238↗
  10. Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Co-author DOI 10.3389/fonc.2023.1218781↗
  11. Increased expression of miR-194-5p through the circPVRL3/miR-194-5p/SOCS2 axis promotes proliferation and metastasis in pancreatic ductal adenocarcinoma by act… Co-author DOI 10.1186/s12935-022-02835-0↗
  12. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.omtn.2019.11.010↗
  13. Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation. Co-author DOI 10.1016/j.ygeno.2020.11.010↗
  14. Establishing and validating a pathway prognostic signature in pancreatic cancer based on miRNA and mRNA sets using GSVA. Co-author DOI 10.18632/aging.103965↗
  15. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription. Co-author DOI 10.7150/thno.44278↗
  16. Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting PLK1 expression. Co-author DOI 10.1016/j.canlet.2018.02.014↗
  17. Retraction notice to "Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting … Co-author DOI 10.1016/j.canlet.2018.09.027↗
  18. microRNA based prognostic biomarkers in pancreatic Cancer. Co-author DOI 10.1186/s40364-018-0131-1↗
  19. Microarray expression profile analysis of circular RNAs in pancreatic cancer. Co-author DOI 10.3892/mmr.2018.8827↗
  20. Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. Co-author DOI 10.1016/j.canlet.2017.03.014↗
  21. Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.19578↗
  22. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Co-author DOI 10.1038/onc.2016.90↗
  23. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Co-author DOI 10.1016/j.canlet.2013.10.009↗
  24. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. Co-author DOI 10.1097/mpa.0000000000000055↗
  25. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0091551↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaizhi Wang · 20 shared papers, 2014–2025 · strength 2.43
  2. Jingyang Yin · 6 shared papers, 2022–2026 · strength 1.29
  3. Jianyou Gu · 6 shared papers, 2020–2026 · strength 1.11
  4. Fuming Xie · 6 shared papers, 2020–2024 · strength 0.84
  5. Jianyou Gu · 4 shared papers, 2020–2025 · strength 0.63
  6. Songsong Liu · 6 shared papers, 2017–2020 · strength 0.50
  7. Junfeng Zhang · 2 shared papers, 2024–2025 · strength 0.46
  8. Bojing Chi · 3 shared papers, 2022–2023 · strength 0.45
  9. Wen Fu · 3 shared papers, 2022–2023 · strength 0.45
  10. Jiali Yang · 2 shared papers, 2024 · strength 0.43
  11. Yunchao Wang · 5 shared papers, 2017–2020 · strength 0.42
  12. Junfeng Zhang · 3 shared papers, 2020–2024 · strength 0.39
  13. Bing Ni · 6 shared papers, 2014–2020 · strength 0.38
  14. Lei Cai · 2 shared papers, 2022–2026 · strength 0.36
  15. Wenjie Huang · 4 shared papers, 2017–2020 · strength 0.34
  16. Yongsheng Ouyang · 5 shared papers, 2014–2020 · strength 0.34
  17. Jingfang Ju · 4 shared papers, 2014–2020 · strength 0.32
  18. Xuejun Xu · 5 shared papers, 2014–2020 · strength 0.32
  19. Xianxing Wang · 3 shared papers, 2020 · strength 0.31
  20. Yingfang Fan · 2 shared papers, 2020–2024 · strength 0.29
  21. J.S. Zhang · 1 shared paper, 2026 · strength 0.26
  22. Huaizhi Wang · 1 shared paper, 2025 · strength 0.25
  23. Hui Chen · 1 shared paper, 2025 · strength 0.25
  24. Tao Zhang · 1 shared paper, 2024 · strength 0.24
  25. Pijiang Sun · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.